Background
==========

Whilst most HIV-positive individuals have a relatively stable renal function over time, some experience a rapid deterioration in their estimated glomerular filtration rate (eGFR) \[[@B1]-[@B5]\]. It is important to identify and assess such individuals and potential risk factors, especially those associated with known risk factors for renal insufficiency. These patients are usually difficult to identify, because as soon as their eGFR decreases, but still remains within a clinically acceptable range, most physicians will switch to non-nephrotoxic antiretroviral drugs \[[@B2]\]. Thus, developing a validated definition of an eGFR slope could guide future studies.

Studying those with initially normal renal function (defined by the Kidney Disease Improving Global Outcomes \[KDIGO\] as eGFR ≥90 ml/min/1.73 m^2^\[[@B6]\]) who experience a rapid decline in their renal function is important, as it could potentially detect kidney impairment at an early stage, before manifest kidney disease has occurred \[[@B7],[@B8]\]. A study from the Modification of Diet in Renal Disease (MDRD) study group, to determine baseline factors that predict the decline in GFR, made a case for rapid decline in renal function to be further investigated. They reported that the mean rate of GFR decline was not significantly related to the baseline GFR, and this suggests an approximately linear mean eGFR decline as renal disease progresses \[[@B9]\]. Rapid progression (RP), an abnormally rapid deterioration in renal function, is a term commonly used in the renal literature. However, unlike CKD (typically defined as two consecutive eGFRs ≤60 ml/min/1.73 m^2^ measured more than 3 months apart), it is without a standardised definition. It is commonly accepted that a normal age-related eGFR decline in the general population (typically \>50 years) is approximately 1 ml/min/1.73 m^2^/year \[[@B10]-[@B12]\]. Therefore, any definition of RP should consider larger changes, and ≥3 ml/min/1.73 m^2^ has been commonly used \[[@B13]-[@B18]\]. However, it is unclear whether a decline of this magnitude is specific enough to accurately identify those at greatest risk of going on to develop CKD. Recent KDIGO guidelines suggest that, for those with evidence of CKD, RP should be defined as a sustained decline of \>5 ml/min/1.73 m^2^ per year \[[@B12]\], although no definition is offered for those with normal baseline renal function. Other definitions of RP have also been used, including a \>50% decrease in baseline eGFR value \[[@B19]\].

The length of time over which an eGFR decline should be sustained to qualify as RP is also unclear \[[@B18]\]. Furthermore, individuals can have differing numbers of eGFR measurements recorded over follow-up. It remains unclear how these multiple measurements have been accounted for; whether an average annual change (i.e. the averaged slope across all available eGFR measurements for an individual, or the average of several yearly changes) or an absolute change over a time period (i.e. the difference between first and last eGFR measurements) has been calculated. This variation in RP definitions limits the ability to make cross-study comparisons.

HIV-positive persons are at increased risk of renal dysfunction compared to the HIV negative population \[[@B1]-[@B5]\], potentially due to high prevalence of traditional renal risk factors \[[@B20],[@B21]\], toxicity from specific antiretroviral drugs \[[@B2]\] and HIV infection itself \[[@B5]\]. As HIV-positive individuals in resource rich settings typically undergo regular renal function testing in accordance with standard screening guidelines, a standardised definition of RP for this population could be beneficial. Therefore, we developed an operational definition for RP in HIV-positive individuals by evaluating the associations between these definitions and traditional renal risk factors. Finally, we investigated the ability of the different definitions to predict future incident CKD.

Methods
=======

Study population
----------------

The D:A:D study is a large observational multi-cohort collaboration of HIV- positive individuals from 11 cohorts in Europe, USA and Australia \[[@B22]\]. All participating cohorts have obtained ethical approval and, if appropriate, informed consent, as required by national guidelines and regulations. Of particular interest to this present analysis, all creatinine measurements on study participants taken as part of routine care from the date of D:A:D study entry onwards were collected. Data were available from nine contributing cohorts. Only measurements taken after 1st January 2004, the date from which monitoring of creatinine levels was routine across these nine cohorts, were included in this analysis.

EGFR calculation
----------------

As some of the cohorts in the D:A:D study are prohibited from collecting data on participants' ethnicity, the Cockroft-Gault (CG) formula was used \[[@B23]-[@B25]\], standardized for body surface area (BSA), as has been done in a previous D:A:D analysis \[[@B2]\]. The closest weight measurement within 12 months of the date of the creatinine measurement was used, alongside height and current age. Where more than one serum creatinine value was measured within 28 days, the median value and mean date across this time period were used.

Included study populations
--------------------------

We identified 22,603 D:A:D study participants with at least three eGFR measurements after 1 January 2004 whose first (baseline) eGFR was ≥90 ml/min/1.73 m^2^. We then assessed the proportion of this initial population that would be eligible to be included in a study of RP, depending on the individuals' length of available follow-up (two, three or four years) and number of measurements per year (≥2 or ≥3) required.

RP definition
-------------

We next developed two definitions of RP (definition A and definition B). We first considered the study population with at least four years of follow-up, and at least three eGFR measurements in each year. We decided that a relatively large annual decline in eGFR ≥5 ml/min/1.73 m^2^ per year would constitute RP. This was to avoid 'noise' introduced by natural eGFR fluctuations, based on advice from nephrologists and in line with the recent KDIGO guidelines \[[@B12]\]. We hypothesised that a RP definition that only considered the difference between the first and last eGFR value (the "absolute decline") may be too susceptible to random eGFR variation. However, a definition that only considers the modelled decline (i.e. fitting a linear slope to all eGFR measurements during follow-up to estimate the average annual eGFR change) may also not fully capture RP, as negative eGFR changes might be compensated by subsequent positive changes, and so our definition captured both elements. In addition, as the clinical implications of RP within normal eGFR ranges are unknown, we restricted our definition to include only those that progressed to an eGFR value below \<90 ml/min/1.73 m^2^. This led to our primary definition of RP (Figure [1](#F1){ref-type="fig"}) as defined below.
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RP: definition a (RPA; Figure [1](#F1){ref-type="fig"})
-------------------------------------------------------

Individuals were considered to have experienced RP over the four year period if they met all of the following three conditions:

1\. Average annual eGFR decline ≥5 ml/min/1.73 m^2^ over four year follow-up period.

2\. Absolute eGFR decline ≥5 ml/min/1.73 m^2^ in two consecutive years (defined using the first and last measurements within each year).

3\. eGFR \<90 ml/min/1.73 m^2^ at the end of the follow-up period.

Secondary definition for RP: definition B (RPB; Figure [2](#F2){ref-type="fig"})
--------------------------------------------------------------------------------

Individuals were considered to have experienced RP under the more restrictive definition B (Figure [2](#F2){ref-type="fig"}) if the following criteria were met:

1\. Absolute decline ≥5 ml/min/1.73 m^2^/year in *each year* of follow-up (defined on the basis of the first and last measurements within each year).

2\. eGFR \<90 ml/min/1.73 m^2^ at the end of the follow-up period.
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Alternative RP definitions
--------------------------

The analyses were repeated using different follow-up periods (three and two years instead of four years) and restriction on the number of measurements per year required to be eligible for inclusion in the analysis (≥2 measurements/year instead of ≥3 measurements/year).

Statistical methods
-------------------

Baseline was defined as the date of first eGFR measurement after 1 January 2004. Logistic regression models were used to assess the association between the different RP definitions and well established traditional renal risk factors - age, hypertension and diabetes \[[@B23]-[@B29]\]. The aim was to ensure that the definition of RP eventually chosen was a suitable compromise between maximising the number of persons eligible to be assessed for RP and the strongest risk factor associations. The C-Statistic was used to determine how well the logistic regression models discriminate between those who experience RP and those who do not. The C-statistic takes values between 0.5 to 1, where 0.5 corresponds to the worst discriminant model (one that performs no better than chance), and 1 corresponds to a model that perfectly discriminates between individuals with and without the outcome \[[@B30]\].

Sensitivity analyses
--------------------

Gender and ethnicity were only considered in additional multivariable logistic regression models, both due to limited numbers of women and individuals of non-Caucasian origin, and also due to conflicting reports about the extent to which these factors are independent predictors of rapid decline in eGFR \[[@B10],[@B11],[@B19],[@B28],[@B31]-[@B33]\]. We also considered a composite endpoint of RP and all-cause mortality. Finally we investigated the number of individuals who would be considered to have RP if a 3 ml/min/1.73 m^2^ decline was considered instead of 5 ml/min/1.73 m^2^.

Additional analyses
-------------------

To check the robustness of our main and alternative RP definitions, we investigated the number of individuals considered to have experienced RP under each definition that went on to develop CKD. Follow-up started at the end of the time period used to define whether an individual experienced RP or not, and any events after this time were considered.

Results
=======

Of 24,799 individuals with normal baseline eGFR, 22,603 (9.1%) had at least three eGFR measurements after 1 January 2004 and could potentially be assessed for RP. A total of 22,603 individuals had normal baseline eGFR ≥90 ml/min/1.73 m^2^, with at least three eGFR measurements after 1 January 2004 and could potentially be assessed for RP. The median number of measurements and length of follow-up was 12 (interquartile range (IQR) 7--16)) and 4.6 (IQR 2.7-6.1) years respectively. The median number of eGFR measurements available per individual per year was 3 (IQR 2--3) years.

Baseline characteristics
------------------------

Table [1](#T1){ref-type="table"} shows the baseline characteristics of individuals included in the analysis. Most of the 22,603 individuals eligible for inclusion in the analysis were male (72.7%), of Caucasian (46.8%) or unknown ethnicity (43.0%), less than 50 years old (90.1%), with BMI in the range of ≥18 to \<26 kg/m^2^ (70.2%), current smokers (42.2%) or ex-smokers (17.4%) and with a current CD4 count ≥350 cell/mm^3^ (65.1%).

###### 

**Baseline**^**a**^**characteristics of patients included in analyses of rapid progression, according to availability of data**

                                                   **Patients with eGFR data available**    **≥4 years follow-up**   **≥3 years follow-up**                                                  
  --------------------------------- -------------- --------------------------------------- ------------------------ ------------------------ --------------- --------------- --------------- ---------------
  Eligible patients                 Number (%)     22603 (100)                                   13061 (57.8)             3655 (16.2)          8298 (36.7)    16165 (71.5)     6375 (28.2)    12283 (54.3)
  Average eGFR                      Median (IQR)   109 (99--123)                                108 (99--122)            107 (98--121)        108 (99--121)   109 (99--122)   108 (99--122)   108 (99--122)
  eGFR \>120 ml/min                 Number (%)     6613 (29.3)                                   3616 (27.7)                943 (26)            225 (27)       4562 (28.1)      1723 (27)       3412 (28)
  Gender                            Male           16438 (72.7)                                  9335 (71.5)              2622 (71.7)          5999 (72.3)    11613 (71.8)     4617 (72.4)     8906 (72.5)
  Race                              White          10573 (46.8)                                  6343 (48.6)              1631 (44.6)          3835 (46.2)     7469 (46.2)     2584 (40.5)     5454 (44.4)
  Black                             1806 (8.0)     1141 (8.7)                                     354 (9.7)                720 (8.7)           1346 (8.3)       581 (9.1)      1023 (8.3)    
  Other                             510 (2.3)      306 (2.3)                                      103 (2.8)                197 (2.4)            385 (2.4)       155 (2.4)       294 (2.4)    
  Unknown                           9714 (43.0)    5271 (40.4)                                   1567 (42.9)              3546 (42.7)          6965 (43.1)     3055 (47.9)     5512 (44.9)   
  Age group                         \>50 years     2238 (9.9)                                     1280 (9.8)               410 (11.2)          868 (10.5)      1641 (10.2)     702 (11.0)      1309 (10.7)
  Hypertension^b^                   Yes            2519 (11.1)                                   1526 (11.7)               494 (13.5)          1030 (12.4)     1865 (11.5)     784 (12.3)      1458 (11.9)
  Diabetes^c^                       Yes            659 (2.9)                                      428 (3.3)                145 (4.0)            290 (3.5)       517 (3.2)       237 (3.7)       413 (3.4)
  Mode of HIV acquisition           Homosexual     10006 (44.3)                                  5642 (43.2)              1611 (44.1)          3710 (44.7)     7028 (43.5)     2876 (45.1)     5487 (44.7)
  IDU                               3058 (13.5)    1783 (13.7)                                    450 (12.3)              1019 (12.3)          2196 (13.6)     740 (11.6)      1540 (12.5)   
  Heterosexual                      8095 (35.8)    4865 (37.3)                                   1385 (37.9)              3081 (37.1)          5952 (36.8)     2359 (37.0)     4499 (36.6)   
  Other                             1444 (6.4)     771 (5.9)                                      209 (5.7)                488 (5.9)            989 (6.1)       400 (6.3)       757 (6.2)    
  BMI at study entry (kg/m^2^)      \<18           633 (2.8)                                      345 (2.6)                 91 (2.5)            216 (2.6)       440 (2.7)       169 (2.7)       330 (2.7)
  ≥18, \<26                         15865 (70.2)   9310 (71.3)                                   2542 (69.6)              5877 (70.8)         11473 (71.0)     4466 (70.1)     8717 (71.0)   
  ≥26, \<30                         3716 (16.4)    2231 (17.1)                                    677 (18.5)              1466 (17.7)          2727 (16.9)     1106 (17.4)     2088 (17.0)   
  ≥30                               1423 (6.3)     845 (6.5)                                      238 (6.5)                536 (6.5)           1037 (6.4)       398 (6.2)       774 (6.3)    
  Unknown                           966 (4.3)      330 (2.5)                                      107 (2.9)                203 (2.5)            488 (3.0)       236 (3.7)       374 (3.0)    
  Hepatitis C^d^ positive           Yes            2765 (12.2)                                   1605 (12.3)               400 (10.9)          910 (11.0)      1958 (12.1)     653 (10.2)      1346 (10.6)
  Hepatitis B^e^ positive           Yes            2773 (12.3)                                   1551 (12.4)               450 (12.3)          1001 (12.1)     1971 (12.2)     816 (12.8)      1501 (12.2)
  Smoking status                    Current        9544 (42.2)                                   5554 (42.5)              1467 (40.1)          3445 (41.5)     6930 (42.9)     2571 (40.3)     5198 (42.3)
  Previous                          3930 (17.4)    2426 (18.6)                                    681 (18.6)              1557 (18.8)          2923 (18.1)     1193 (18.7)     2248 (18.3)   
  Never                             5824 (25.8)    3599 (27.6)                                   1086 (29.7)              2332 (28.1)          4314 (26.7)     1726 (27.1)     3299 (26.9)   
  Unknown                           3305 (14.6)    1482 (11.4)                                    421 (11.5)               964 (11.6)          1998 (12.4)     885 (13.9)      1538 (12.5)   
  Current CD4 count (cells/mm^3^)   \<200          2823 (12.5)                                   1435 (11.0)               482 (13.2)          940 (11.3)      1831 (11.3)     833 (13.1)      1424 (11.6)
  200-349                           4912 (21.7)    2797 (21.4)                                    826 (22.6)              1807 (21.8)          3427 (21.2)     1444 (22.7)     2641 (21.5)   
  350-499                           5565 (24.6)    3294 (25.2)                                    963 (26.4)              2109 (25.4)          4049 (25.1)     1632 (25.6)     3078 (25.1)   
  ≥500                              9145 (40.5)    5492 (42.1)                                   1371 (37.5)              3417 (41.2)          6779 (41.9)     2432 (38.2)     5079 (41.4)   
                                    Missing        158 (0.7)                                       43 (0.3)                 13 (0.4)            25 (0.3)        79 (0.5)        34 (0.5)        61 (0.5)

*Abbreviations*: eGFR, estimated glomerular filtration rate; IDU, injecting drug user;

^a^Baseline was defined as the defined as the time, during prospective follow-up, of the first eGFR measurement on or after 1 January 2004.

^b^Hypertension was defined as a blood pressure of ≥150/≥100 mmHg or use of antihypertensive drugs and ace inhibitors.

^c^Diabetes was defined as receipt of antidiabetic treatment or verification of diabetes in a case report form.

^d^Hepatitis C was defined as detection of antibody to HCV plus detection or unknown presence of HCV RNA.

^e^Hepatitis B was defined as detection of HBV surface antigen, detection of HBV e antigen, or detection of HBV DNA plus antibody to HBV e antigen.

^f^Unrestricted was defined as no restriction concerning the number of eGFR measurements obtained per year.

There were 13,061 individuals with at least four years follow-up, and of these 3,655 (16.2% of the original 22,603 participants) had ≥3 measurements/year and 8,298 (36.7%) had ≥2 measurements/year. There were 16,165 individuals with at least three years of follow-up; of these 6,375 (28.2%) had ≥3 measurements/year, and 12,283 (54.3%) had ≥2 measurements/year (Table [1](#T1){ref-type="table"}). Finally, 19,309 individuals had at least two years of follow-up; 10,756 (47.6%) had ≥3 measurements/year, and 17,211 (76.1%) had ≥2 measurements/year (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). The characteristics of those eligible for assessment for RP using the primary definition were similar to all included (Table [1](#T1){ref-type="table"}), as for the other RP definitions based on varying follow-up periods and number of eGFR measurements/year.

Percentage experiencing RP
--------------------------

The average rate of eGFR decline for all participants was -3.91 ml/min/1.73 m^2^ /year (95% confidence interval; -11.7, 3.8 ml/min/1.73 m^2^/year). Of the 3,655 individuals with ≥ 4 four years' follow-up and ≥3 measurements/year, 108 (3.0%; Figure [3](#F3){ref-type="fig"}) experienced RP according to definition A. Similar proportions were considered to have experienced RP when considering shorter follow-up periods of three years (195/6375; 3.1%) and two years (355/10756; 3.3%). In contrast under RP definition B, considerably greater proportions were considered to have experienced RP regardless of whether two (476/10756; 4.4%), three (48/6375; 0.8%) or four (15/3655; 0.4%) years' follow-up was considered.

![**Proportion of patients that satisfy different RP definitions, for decline of 5 or 3 ml/min/1.73 m**^**2**^**.**](1471-2369-15-51-3){#F3}

When two annual eGFR measurements were required instead of three, similar proportions experienced RP under definition A, irrespective of the length of follow-up period (256/8298 (3.1%) experienced RP using four years follow-up, 369/12283 (3.0%) using three years follow-up, and 602/17211 (3.5%) using two years follow-up). The same was also true for RP definition B. Thus, it appears that the requirement for two or three eGFR measurements per year did not impact greatly on the proportion of individuals considered to be rapid progressors. When using a decline of 3 ml/min/1.73 m^2^ instead of 5 ml/min/1.73 m^2^ to define RP, the percentage of individuals that progressed to RP increased as expected across all strata (Figure [3](#F3){ref-type="fig"}).

Association between traditional renal risk factors and rapid progression (RP)
-----------------------------------------------------------------------------

In a multivariable logistic regression, the odds ratios (OR) for the association between age \>50 years and RP were strong for every definition (Table [2](#T2){ref-type="table"}); they varied between 1.90 to 2.54 for the primary definition (RP definition A) and between 2.55 to 2.80 for RP definition B. In contrast, there was more variation for the association with hypertension, and the strength depended on the length of follow-up. No associations between hypertension and RP were found when two years of follow-up was considered (the ORs varied between 0.99 and 1.14), whereas for three and four years of follow-up an association was generally found, although not all reached statistical significance at the 5% level. No RP definition demonstrated a clear association with diabetes (ORs varied between 0.48 to 1.24).

###### 

**Associations**^**\$**^**between different rapid progression of renal function definitions and traditional renal disease risk factors**

                                     **With at least three eGFR measurements**   **With at least two eGFR measurements**                                                                                      
  -------------- ------------------ ------------------------------------------- ----------------------------------------- -------------------------- ------------------ ------------------ ------------------ ---------
  Four           Age \>50 years                  1.90 (1.15-3.14)                                 0.01                                \*              2.33 (1.69-3.20)       \<0.001        2.65 (1.27-5.53)    0.01
  Hypertension   1.42 (0.85-2.37)                      0.19                                 1.41 (1.00-1.97)                         0.05             1.31 (0.55-3.10)         0.54                           
  Diabetes       1.06 (0.44-2.54)                      0.90                                 0.88 (0.47-1.60)                         0.68             0.48 (0.06-3.62)         0.48                           
  Three          Age \>50 years                  1.91 (1.31-2.77)                                \<0.001                   2.75 (1.64-4.59) \<0.001   2.07 (1.58-2.71)       \<0.001        2.80 (1.95-4.04)   \<0.001
  Hypertension   1.58 (1.08-2.33)                      0.02                               1.31 (0.71-2.40) 0.39                1.39 (1.04-1.85)             0.03         0.79 (0.49-1.28)         0.34        
  Diabetes       0.91 (0.45-1.83)                      0.64                               1.16 (0.45-3.00) 0.76                0.94 (0.56-1.59)             0.82         1.24 (0.62-2.51)         0.54        
  Two            Age \>50 years                  2.32 (1.78-3.04)                                \<0.001                   2.70 (2.15-3.39) \<0.001   2.54 (2.06-3.12)       \<0.001        2.55 (2.07-3.14)   \<0.001
  Hypertension   1.09 (0.80-1.50)                      0.58                               1.14 (0.87-1.49) 0.36                0.99 (0.78-1.27)             0.96         1.00 (0.78-1.28)         0.99        
                 Diabetes                        0.92 (0.53-1.61)                                 0.78                      0.73 (0.43-1.23) 0.24     1.14 (0.67-1.95)         0.62         0.98 (0.64-1.51)    0.93

RP definition A: First eGFR \>90; average slope during follow-up ≥5 per year; absolute decline ≥5 in two consecutive years; last eGFR \<90.

RP definition B: First eGFR \>90; absolute decline ≥5 in all years of follow-up; last eGFR \<90.

^\$^Results from multivariable logistic regression analysis.

\*Insufficient numbers experiencing RP with this definition.

The C-Statistics for these logistic regression models were very similar in magnitude, ranging from 0.56 to 0.62, for both definitions A and B. Addition of gender and ethnicity to these models did not substantively change the results (results not shown). The composite endpoint of RP and mortality markedly increased the number of events as expected, but the association with age and hypertension in the logistic regression remained similar (results not shown).

Progression to CKD
------------------

For the primary definition of RP (definition A with 4 years' follow-up and at least 3 measurements per year), 13 (12%) individuals who experienced RP progressed to CKD by the end of the follow-up period (i.e. the test had a positive predictive value \[PPV\] of 12%), whereas only 21 (0.6%) of those without RP progressed to CKD (i.e. one minus the negative predictive value \[NPV\] was 0.6%, or NPV = 99.4%; Table [3](#T3){ref-type="table"}). These values corresponded to sensitivity and specificity for the primary definition of 38.2% and 97.4%, suggesting RP from initial normal eGFR levels is not a good marker for subsequent CKD, within the timeframes analysed in this study. As the definition of RP became less restrictive (with fewer years of follow-up and number of eGFR measurements/year), fewer of those who experienced RP progressed to CKD (PPV estimates decreased from 12% to 3.3%), whereas the proportion of those not experiencing RP, who did progress to CKD remained constant (1-NPV varied from 0.4% to 0.6%). For RP definition B, the PPV and sensitivity estimates were generally smaller compared to obtained from definition A, and the specificity and (1-NPV) estimates were similar. When using an eGFR decline of 3 instead of 5 ml/min/1.73 m^2^ to define RP, the proportion that progressed to CKD (i.e. the PPV) decreased (Table [3](#T3){ref-type="table"}). Much weaker associations were seen when an endpoint of CKD or death was considered (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2).

###### 

Percentage who progressed to incident CKD\*, according to different definitions of RP

  **Years of follow-up considered**   **Number of eGFR per year**   **Excluded in analysis**                                 **RP definition A**                                 **RP definition B**                                                       
  ----------------------------------- ----------------------------- -------------------------- -------------------------------------------------------------------------------- --------------------- ------ ------ -------------- ---------------- ------ ------
  Four                                Three                         65/18948 (0.3)                                               13/108(12.0)                                       21/3547 (0.6)      38.2   97.4    0/15 (0.0)    34/3640 (0.9)    0.0    99.6
  Four                                Two                           42/14305 (0.3)                                               23/256 (9.0)                                       34/8042 (0.4)      40.4   97.2    2/43 (4.7)    55/8255 (0.7)    3.5    99.5
  Three                               Three                         47/16228 (0.3)                                               15/195 (7.7)                                       37/6180 (0.6)      28.8   97.2    4/85 (4.7)    48/6290 (0.8)    7.7    98.7
  Three                               Two                           24/10320 (0.2)                                               20/369 (5.4)                                      55/11914 (0.5)      26.7   97.1   7/173 (4.1)    68/12110 (0.6)   9.3    98.6
  Two                                 Three                         28/11847 (0.2)                                               14/355 (3.9)                                      57/10401 (0.6)      19.7   96.8   16/476 (3.4)   55/10280 (0.5)   22.5   95.7
  Two                                 Two                           7/5392 (0.1)                                                 20/602 (3.3)                                      72/16609 (0.4)      21.7   96.6   23/779 (3.0)   69/16432 (0.4)   25.0   95.6
                                                                                                **Declines of \>3 ml/min/1.73 m**^**2**^**required to meet the RP definition**                                                                             
  Four                                Three                         65/18948 (0.3)                                               18/218 (8.3)                                       16/3437 (0.5)      52.9   94.5    3/37 (8.1)    31/3618 (0.9)    8.8    99.1
  Four                                Two                           42/14305 (0.3)                                               27/506 (5.3)                                       30/7792 (0.4)      47.4   94.2    6/97 (6.2)    51/8201 (0.6)    10.5   98.9
  Three                               Three                         47/16228 (0.3)                                               21/325 (6.5)                                       31/6050 (0.5)      40.4   95.2   8/151 (0.7)    44/6224 (27.5)   15.4   97.7
  Three                               Two                           24/10320 (0.2)                                               25/602 (4.2)                                      50/11681 (0.4)      33.3   95.3   14/292 (4.8)   61/11991 (0.5)   18.7   97.7
  Two                                 Three                         28/11847 (0.2)                                               20/527 (3.8)                                      51/10229 (0.5)      28.2   95.3   22/633 (2.8)   49/10123 (0.5)   31.0   94.3
  Two                                 Two                           7/5392 (0.1)                                                 30/885 (3.4)                                      62/16326 (0.4)      32.6   95.0   32/1021(4.5)   60/16190 (0.4)   34.8   94.2

\*Two consecutive eGFR measurements \<60 ml/min/1.73 m^2^.

^a^RP: Rapid Progressors who developed CKD (i.e., the positive predictive value (PPV)).

^b^Non-RP: non-Rapid Progressors who developed CKD (i.e., 1-negative predictive value (NPV)).

Discussion
==========

This manuscript considered an operational definition of RP in HIV-positive individuals. Our results suggest a definition that would apply to individuals with normal baseline eGFR (≥90 ml/min/1.73 m^2^) with at least three years' follow-up and at least two eGFR measurements per year, for the reasons described in subsequent paragraphs. Rapid progressors are defined as those who had: (i) an average decline over the three-year period of ≥5 ml/min/m^2^ per year, (ii) an eGFR decline ≥5 ml/min/1.73 m^2^ in two consecutive years and (iii) an eGFR at the end of the three year period of \<90 ml/min/1.73 m^2^ (RP definition A). This definition allows inclusion of a reasonable number of individuals that are broadly representative of the study cohort. It also had reasonable discriminatory ability to identify those who would go on to develop incident CKD, although none demonstrated particularly strong prognostic ability. However, as follow up after having experienced RP is still relatively short, later studies will show if those experiencing RP will be at higher risk of CKD and mortality in the longer term \[[@B34]\].

In deriving a definition for RP, we considered an annual decline ≥5 ml/min/1.73 m^2^ instead of the ≥3 ml/min/1.73 m^2^ decline as previously reported \[[@B13]-[@B18]\]. This ensured that only clinically relevant events were identified by reducing the impact of the "noise" that is introduced by random variability in eGFR measurements \[[@B9]\] and secondly this cut-off agrees with new guidelines from KDIGO \[[@B12]\]. When we considered a cut-off of ≥3 ml/min/1.73 m^2^ in sensitivity analyses, we found a much larger proportion defined as having RP, weaker associations with traditional renal risk factors, and less predictive ability with respect to future development of CKD. Additionally, the KDIGO guidelines do not specify progression in those without pre-existing CKD, which is the study population included in this present analysis. Limiting the definition to those whose final eGFR is outside of the normal range (i.e. \<90 ml/min/1.73 m^2^) should hopefully ensure that any changes in eGFR are clinically relevant.

RP definition A gave more consistent percentages than RP definition B, where the percentage considered as RPs varied from 0.4% to 4.5%, as shown in Figure [3](#F3){ref-type="fig"}, depending on the length of follow-up and number of measurements per year considered. Furthermore, a higher percentage of those with RP under definition A progressed to CKD compared to definition B. As RP definition A combines absolute and average renal function decline, it is based on all available eGFR and is less restrictive (in particular for longer follow-up) and therefore may better reflect the dynamics of RP than definition B. One potential limitation of our RP definition is that we did not base our definitions on relative (percentage) changes. There have been suggestions that a 25% decline from baseline in eGFR levels may be an appropriate definition for RP \[[@B12]\].

For individuals with at least two eGFR measurements per year, requirement of at least three years of follow-up captures more eligible individuals into the RP analyses compared to those with four years of follow-up, which was the follow-up period considered in our original primary definition. Shorter periods of follow-up with more included individuals are more likely to ensure a more inclusive study population and more statistical power to identify associations. Clearly, the longer the follow-up period, the more likely we are to introduce selection bias, with those with the worst predicted outcome being excluded if they had died or dropped out of the study due to ill health. Therefore, the choice of two or three years' follow-up could be taken in an attempt to minimise selection bias, although one cannot ever definitively exclude this. Conversely, two years may be too short a time period to permit accurate determination of RP,therefore, three years appeared most suitable.

Requirement of three rather than two eGFR measurements/year provides a more reliable slope and identifies a greater proportion progressing to CKD. Two measurements per year may however, be more applicable in routine clinical care, particularly as there is a move towards less frequent laboratory monitoring of HIV positive individuals. In this study there was a median of three creatinine measurements per individual per year, which means that any definition of RP that requires three or more measurements performed each year is unlikely to be operational due to high proportions being excluded.

In our definition of RP, the proportion of RPs who progressed to CKD were ten--fold higher than non-RPs who progressed to CKD, though the sensitivity for these results were low, regardless of the definition used. This suggests that RP is not necessarily predictive of incident CKD, perhaps because treatment switches away from potentially nephrotoxic drugs are made before incident CKD has occurred \[[@B32]\] or because longer follow-up would be needed to detect subsequent CKD events.

We used a small and selective number of variables, defined a priori, to investigate their association with each of our definitions of RP \[[@B23]-[@B29]\]. Our current analysis found the strong association between age and hypertension with RP when using our primary definition A. In contrast, it was difficult to reach any conclusions for diabetes, where associations were small or suggested a protective effect. Addition of gender and ethnicity to the logistic model made no changes to the results \[[@B10],[@B17],[@B19],[@B21],[@B28],[@B31]-[@B33]\].

A composite endpoint of RP and all-cause mortality provided more endpoints as expected, but a similar magnitude of the association between age, hypertension and diabetes. As very few deaths in HIV-positive individuals were attributable to renal disease, including all-cause mortality in the endpoint did not give a more sensible definition of RP. Therefore, we would not recommend using a combined endpoint of all-cause mortality and RP.

In this analysis we have not considered exposure to antiretroviral treatment, as our aim was not to study factors associated with RP, but rather to develop a definition of RP that can be used in the future in such studies. Scherzer et al. demonstrated that tenofovir use was associated with rapid decline in renal function, where rapid decline was defined as an annual decline of 3 ml/min/1.73 m^2^ for two consecutive years, but not specified if absolute or average \[[@B18]\].

Sensitivity analyses with eGFR calculated from the MDRD or CKD-EPI equations \[[@B35],[@B36]\], were not carried out, as both of these methods required ethnicity, which some of the participating cohorts in the D:A:D study are prohibited from collecting. However, recent studies have suggestedthat consistent results are obtained regardless of the estimation used \[[@B37],[@B38]\], although other studies have not found this \[[@B38]-[@B40]\]. Furthermore, the CG formula was adjusted for BSA, in line with previous D:A:D analyses \[[@B2]\] and there are conflicting reports regarding whether this is appropriate \[[@B41],[@B42]\]. Analyses performed on this cohort on standardising for BSA suggests that it has little impact on obtained eGFRs (Prof A Mocroft, personal communication).

In the D:A:D study, no systematic information is collected on proteinuria, which is a reliable marker for rapid eGFR decline \[[@B31]\]. Furthermore, the C-Statistic values obtained were in the range of 0.56 to 0.62 and so the ability of the logistic model to discriminate between those with and without RP would only be considered 'satisfactory' using Hosmer and Lemeshow's criteria \[[@B43]\]. Using multiple endpoints with different length of follow-up and number of measurements in order to identify a model that best fits our selected variables associated with RP may lead to us finding a false positive result.

Conclusions
===========

In this analysis, we have developed a standardised operational definition for rapid progression of eGFR. We believe this definition balances practical issues regarding the data likely to be available in standard HIV observational databases with a definition that has clinical relevance. Under this definition, 3% of those with normal eGFR went on to develop RP (definition A), and of these 5.4% (20/369) progressed to CKD during a median of 5.6 years of follow-up, including the follow-up used to define individuals as experiencing RP or not.

Despite the weak association between our RP definition and subsequent development of CKD, perhaps due to the limited follow-up available, other studies have shown that short-term changes in eGFR relate to subsequent mortality and underline the clinical importance of RP. In future analyses, the D:A:D study group will consider this definition of RP to identify and assess potential risk factors including antiretroviral use, as a dynamic tool to be used in addition to commonly used CKD analysis.
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